BAP1-TPDS—germline BAP1 mutations confer an elevated risk of clear-cell RCC—albeit less frequently—alongside uveal melanoma and mesothelioma; 2023 European guidance outlines surveillance for carriers [42]. Here, BAP1 is linked to uveal melanoma.